RBC Capital analyst Brian Abrahams raised the firm’s price target on PTC Therapeutics (PTCT) to $82 from $78 and keeps a Sector Perform rating on the shares. The company’s pre-reported Q4 Sephience sales and guidance reflect the meaningful revenue opportunity for the company that should more than offset DMD franchise erosion and drive profitability, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target lowered to $93 from $97 at BofA
- Sephience-Led Growth, Global Expansion, and Robust Pipeline Underpin Buy Rating on PTC Therapeutics
- PTC Therapeutics price target lowered to $86 from $93 at Wells Fargo
- PTC Therapeutics: Sephience Uptake, Advancing Pipeline, and Strengthening Financials Support Buy Rating
- Balanced Outlook on PTC: Sephience-Driven Growth Offset by Duchenne Headwinds and Unmodeled Vatiquinone Upside Supports Hold Rating